Fall, 2015

The hidden face of Janus 

 In this issue:  CHZ868, an experimental Type II JAK2 inhibitor targets inactive state of JAK2, rolls back MPN symptoms, reduces allele burden, and overcomes ruxolitinib resistance.   Plus: Molecular modeling of the autoinhibitory action between the kinase and pseudokinase uncovers hidden pathogenic mechanism.

 Note: Ross Levine, MD to discuss his CHZ868 work in the September 16, 2015  MPNforum Magazine

\

    About MQJ    Subscribe

. 

  © MPN Quarterly Journal, 2015. This work is licensed under a Creative Commons Attribution-NonCommercial No-Derivs 3.0 Unported License. MPNquarterly@gmail.com